2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Unknown
1
Recruiting
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Classical hematology
2
Gynecologic
1
Conditions
Anemia, Iron-Deficiency
2
Anemia
1
Interventions
Cyclophosphamide
94
fludarabine phosphate
87
Busulfan
64
Cyclosporine
57
Epoetin Alfa
55
Peripheral Blood Stem Cell Transplantation
54
Mycophenolic Acid
54
Whole-Body Irradiation
53
fludarabine
45
Antilymphocyte Serum
43
Filgrastim
41
Cytarabine
41
Melphalan
40
Tacrolimus
39
Darbepoetin alfa
39
Methotrexate
34
Radiotherapy
33
Cord Blood Stem Cell Transplantation
28
Granulocyte Colony-Stimulating Factor
23
apixaban
22
Methylprednisolone
22
Rivaroxaban
21
Etoposide
21
Thiotepa
17
Dalteparin
17
eltrombopag
16
ferric carboxymaltose
14
epoetin beta
14
Daunorubicin
14
Azacitidine
14
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
ferric derisomaltose
×
Classical hematology
×
Clear all
NCT05407987
2025-04-25
FORGE II
AHS Cancer Control Alberta
Phase 3
Recruiting
82 enrolled
NCT05467319
2022-07-20
FORGE
Alberta Health Services, Calgary
Phase 3
Unknown
82 enrolled